Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Women make up more than 50% of adults living with human immunodeficiency virus (HIV) infection or the acquired immunodeficiency syndrome (AIDS) in sub-Saharan Africa. Thus, female-initiated HIV prevention methods are urgently needed. METHODS: We performed a randomized, double-blind, placebo-controlled trial of cellulose sulfate, an HIV-entry inhibitor formulated as a vaginal gel, involving women at high risk for HIV infection at three African and two Indian sites. The primary end point was newly acquired infection with HIV type 1 or 2. The secondary end point was newly acquired gonococcal or chlamydial infection. The primary analysis was based on a log-rank test of no difference in the distribution of time to HIV infection, stratified according to site. RESULTS: A total of 1398 women were enrolled and randomly assigned to receive cellulose sulfate gel (706 participants) or placebo (692 participants) and had follow-up HIV test data. There were 41 newly acquired HIV infections, 25 in the cellulose sulfate group and 16 in the placebo group, with an estimated hazard ratio of infection for the cellulose sulfate group of 1.61 (P=0.13). This result, which is not significant, is in contrast to the interim finding that led to the trial being stopped prematurely (hazard ratio, 2.02 [corrected]; P=0.05 [corrected]) and the suggestive result of a preplanned secondary (adherence-based) analysis (hazard ratio, 2.02; P=0.05). No significant effect of cellulose sulfate as compared with placebo was found on the risk of gonorrheal infection (hazard ratio, 1.10; 95% confidence interval [CI], 0.74 to 1.62) or chlamydial infection (hazard ratio, 0.71; 95% CI, 0.47 to 1.08). CONCLUSIONS: Cellulose sulfate did not prevent HIV infection and may have increased the risk of HIV acquisition. (ClinicalTrials.gov number, NCT00153777; and Current Controlled Trials number, ISRCTN95638385.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonspecific topical microbicides are ineffective for preventing HIV infection (40–45).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [43]
Citations
Cites
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020298 · Cited by 2,451
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.
Bailey, R. C., Moses, S., Parker, C. B., Agot, K., Maclean, I., Krieger, J. N., Williams, C. F., Campbell, R. T., & Ndinya-Achola, J. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60312-2 · Cited by 2,292
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.
Gray, R. H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., Kiwanuka, N., Moulton, L. H., Chaudhary, M. A., Chen, M. Z., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60313-4 · Cited by 2,226
Effect of Herpes Simplex Suppression on Incidence of HIV among Women in Tanzania
Watson-Jones, D., Weiss, H. A., Rusizoka, M., Changalucha, J., Baisley, K., Mugeye, K., Tanton, C., Ross, D., Everett, D., Clayton, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800260 · Cited by 371
Padian, N. S., van der Straten, A., Ramjee, G., Chipato, T., de Bruyn, G., Blanchard, K., Shiboski, S., Montgomery, E. T., Fancher, H., Cheng, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60950-7 · Cited by 337
Self-citationTien, D., Schnaare, R. L., Kang, F., Cohl, G., McCormick, T. J., Moench, T. R., Doncel, G., Watson, K., Buckheit, R. W., Lewis, M. G., et al. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.845 · Cited by 178
One Step Forward, Two Steps Back — Will There Ever Be an AIDS Vaccine?
Steinbrook, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmp0708117 · Cited by 150
Mauck, C. K., Weiner, D. H., Ballagh, S. A., Creinin, M. D., Archer, D. F., Schwartz, J. L., Pymar, H. C., Lai, J.-J., & Callahan, M. M. (2001) · Contraception · doi:10.1016/s0010-7824(01)00271-2 · Cited by 92
Methodological Challenges in Biomedical HIV Prevention Trials
Institute of Medicine (2008) · National Academies Press eBooks · doi:10.17226/12056 · Cited by 89
Schwartz, J. L., Mauck, C. K., Lai, J.-J., Creinin, M. D., Brache, V., Ballagh, S. A., Weiner, D. H., Hillier, S. L., Fichorova, R. N., & Callahan, M. M. (2006) · Contraception · doi:10.1016/j.contraception.2006.02.008 · Cited by 83
Balzarini, J. M., Herrewege, Y. V., Vermeire, K., Vanham, G., & Schols, D. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.030155 · Cited by 79
Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women
El-Sadr, W. M., Mayer, K. H., Maslankowski, L., Hoesley, C. J., Justman, J. E., Gai, F., Mauck, C. K., Absalon, J., Morrow, K. M., Mâsse, B. R., et al. (2006) · AIDS · doi:10.1097/01.aids.0000226950.72223.5f · Cited by 77
Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides
NEURATH, A. R., Strick, N., & Li, Y. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-150 · Cited by 75
Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel
Malonza, I., Mirembe, F. M., Nakabiito, C., Odusoga, L. O., Osinupebi, O. A., Hazari, K. T., Chitlange, S., Ali, M. M., Callahan, M. M., & Damme, L. V. (2005) · AIDS · doi:10.1097/01.aids.0000194797.59046.8f · Cited by 56
Self-citationCellulose sulfate: tolerance and acceptability of penile application
Mauck, C. K., Frezieres, R. G., Walsh, T. L., Robergeau, K., & Callahan, M. M. (2001) · Contraception · doi:10.1016/s0010-7824(01)00270-0 · Cited by 38
Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days
Doh, A. S., Ngoh, N. N., Roddy, R. E., Lai, J.-J., Linton, K., & Mauck, C. K. (2007) · Contraception · doi:10.1016/j.contraception.2007.05.083 · Cited by 25
Noncomparative Contraceptive Efficacy of Cellulose Sulfate Gel
Mauck, C. K., Freziers, R. G., Walsh, T. L., et al. (2008) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181644598 · Cited by 25
Safety Trial of the Vaginal Microbicide Cellulose Sulfate Gel in HIV-Positive Men
Jespers, V., Buvé, A., & Damme, L. V. (2007) · Sexually Transmitted Diseases · doi:10.1097/01.olq.0000253340.76118.89 · Cited by 15
Research works printed but not linked: 4
- Saifuddin M, Doncel GF, Tsai L, Gettie A, Bhom R, Cheng-Mayer C. Intravaginal administration of 6% cellulose sulfate gel prevented systemic infection in rhesus macaques in a multiple dose R5/X4 SHIV vaginal challenge model. Presented at the Late Breaker Session, Microbicides 2008 Conference, Delhi, India, February 24–27, 2008.
- Johansson E. Results of phase III Carraguard trial. Presented at the Microbicides 2008 Conference, Delhi, India, February 24–27, 2008.
- Halpern V, Wang L, Obunge O, et al. Effectiveness of cellulose sulfate gel for prevention of HIV: results of the phase III trial in Nigeria. Presented at the Late Breaker Session of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, July 22–25, 2007.
- Celum C, Wald A, Hughes J, et al. HSV-2 suppressive therapy for prevention of HIV acquisition: results of HPTN 039. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 3–6, 2008.
Cited by
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually Transmitted Diseases Treatment Guidelines, 2010
(2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,076
HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities
Kharsany, A. B. M., & Karim, Q. A. (2016) · The Open AIDS Journal · doi:10.2174/1874613601610010034 · Cited by 980
Phillips, K. A., Bales, K. L., Capitanio, J. P., Conley, A., Czoty, P. W., ‘t Hart, B. A., Hopkins, W. D., Hu, S., Miller, L. A., Nader, M. A., et al. (2014) · American Journal of Primatology · doi:10.1002/ajp.22281 · Cited by 612
Skoler-Karpoff, S., Ramjee, G., Ahmed, K., Altini, L., Plagianos, M. G., Friedland, B., Govender, S., De Kock, A., Cassim, N., Palanee, T., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61842-5 · Cited by 502
Self-citation
Metadata
- Authors
- Van Damme, L., Govinden, R., Mirembe, F. M., Guédou, F., Solomon, S., Becker, M. L., Pradeep, B. S., Krishnan, A. K., Alary, M., Pande, B., Ramjee, G., Deese, J., Crucitti, T., & Taylor, D.
- Affiliations
- South African Medical Research Council (ZA)
- Makerere University (UG)
- Centre hospitalier affilié universitaire de Québec (CA)
- University of Manitoba (CA)
- St.John's Medical College Hospital (IN)
- Family Health International 360 (US)
- Instituut voor Tropische Geneeskunde (BE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-07-31
- Volume
- 359
- Issue
- 5
- Pages
- 463-472
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1994566416
- Cited by
- 438
- References
- 23
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 4 · 2021: 16 · 2020: 15 · 2019: 7 · 2018: 8 · 2017: 12 · 2016: 19 · 2015: 26 · 2014: 30 · 2013: 49 · 2012: 59
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Keywords
- cellulose sulfate, vaginal gel, HIV prevention, HIV entry inhibitors, gonorrhea, chlamydia, sub-Saharan Africa, India
- MeSH terms
- Administration, Intravaginal, Adult, Cellulose, Chlamydia Infections, Double-Blind Method, Female, Gels, Gonorrhea, Humans, Placebos, Sexual Behavior, HIV Infections, Treatment Failure, Disease Transmission, Infectious, Anti-HIV Agents, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.